UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
| |||
(State or Other Jurisdiction |
| (Commission File |
| (IRS Employer |
(Address of principal executive offices and Zip Code) | ||
(
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01Regulation FD Disclosure.
As previously announced, effective October 1, 2023, Azenta, Inc. (the “Company”) realigned its organizational structure to three principal business segments to enhance its commercial strategy for accelerating growth and to enable additional profitability initiatives. The Company’s operating and reportable segments effective in the first quarter of fiscal 2024 (which align with how the Company’s Chief Operating Decision Maker manages the business, allocates resources, and assesses performance) consist of the following:
| ● | Multiomics. The Multiomics business resources operate under a single business unit that provides genomic and other sample analysis services, including gene sequencing and gene synthesis. |
| ● | Sample Management Solutions. Sample & Repository Solutions, Ultracold Systems, and Consumables and Instruments resources operate as a single business unit offering end-to-end sample management services and products. |
| ● | B Medical Systems. B Medical Systems business resources operate as a single business unit focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. |
For informational purposes, included in Exhibit 99.1 to this report, and incorporated into this Item 7.01 by reference, is the Company’s historical recast of segment information that reflects the segment changes noted above for fiscal years 2023 and 2022 and the quarters therein.
Limitation on Incorporation by Reference. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
Exhibit | Description | |
99.1 | Supplemental Information – Historical Recast of Segment Information | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AZENTA, INC. | ||
/s/ Jason W. Joseph | ||
Date: January 31, 2024 | Jason W. Joseph | |
Senior Vice President, General Counsel and Secretary | ||